Could Viagra Help Fight Cancer? Study Finds Surprising Cholesterol Link

Viagra Plus Statins Tied to Better Cancer Survival Odds, Study Suggests

Viagra has been quietly racking up a second résumé. Best known for treating erectile dysfunction, sildenafil turns out to have a separate, previously unrecognized effect inside cancer cells: it appears to disrupt their cholesterol supply, potentially leaving them poorly equipped to spread through the body.

A new study published in Cancer Research found that sildenafil disrupts how cancer cells handle cholesterol, a fat tumors depend on to build the flexible membranes they need to invade new tissue. By trapping cholesterol inside a cellular recycling compartment, the drug may limit how much cholesterol cancer cells have to work with. Mouse experiments across breast, lung, and colon cancer models, conducted in female mice, showed reduced metastasis, while cell-line experiments showed reduced migration and viability.

An analysis of health records from more than 40,000 male cancer patients found that men who had filled at least three sildenafil prescriptions in the six months before diagnosis and also used statins were associated with a 31% lower risk of death within five years, compared to those who used neither drug.

Sildenafil Traps Cholesterol Inside Cancer Cells

Cholesterol has a bad reputation in heart disease, but inside cells it’s a building material for outer walls and internal parts. Tumor cells breaking away from a primary mass need a lot of it to rebuild those walls and push through surrounding tissue.

Sildenafil works by blocking an enzyme called PDE5a. That enzyme’s job is to break down a molecule called cGMP, so blocking it lets cGMP build up. This is the same chemistry behind Viagra’s original use: more cGMP relaxes blood vessels. But the research team found that cGMP does something else entirely once it’s inside a cancer cell. It attaches to a protein called NPC1, which normally acts like a delivery truck, hauling cholesterol out of the cell’s internal trash-and-recycling depot (a compartment called a lysosome) and out to where the cell can actually use it. When cGMP builds up and jams that delivery truck, cholesterol piles up inside the depot instead of reaching the rest of the cell.

Cancer cells respond by trying to make their own cholesterol from scratch, flipping on an internal alarm switch. But it isn’t enough. Usable cholesterol still runs low, the cell’s outer wall gets flimsier, and its power plants sputter. Cells in that state struggle to migrate, invade nearby tissue, or spread to new organs.

Sildenafil Cuts Metastasis Across Multiple Cancer Types

Investigators tested sildenafil in three mouse cancer models, breast, lung, and colon, all in female mice. In every case, the drug cut lung metastases. In the breast cancer model, sildenafil barely touched the tumor’s size but slashed the number of metastatic colonies reaching the lungs.

To rule out a fluke, the team tried a related drug, vardenafil, and got the same result, then shut down the PDE5a gene directly and saw the same drop in metastases, evidence that the enzyme is what matters. The pattern held even in mice with badly weakened immune systems, pointing to sildenafil acting on tumor cells directly.

Across human cancer cell lines involving breast, prostate, colon, and lung cancers, sildenafil restricted cell movement and viability. Triple-negative breast cancer cells derived from patient tumors and grown in mouse models showed the same pattern: cholesterol-making machinery ramped up, usable cholesterol fell, and stored cholesterol piled up, signs of a cell stuck in a traffic jam it couldn’t clear.

Combining Sildenafil With Statins Improves Cancer Patient Survival

Statins, among the most widely prescribed drugs in the world, work by cutting cholesterol production at the source. Pairing sildenafil with a statin could block both the supply route and the recycling route at once.

Laboratory experiments supported that idea. Adding the statin lovastatin to sildenafil cut cancer cell movement and colony growth further than either drug alone, and pushed more cancer cells to die off. The combination barely touched healthy, noncancerous cells in the same experiments, a difference tied to cancer cells’ weaker internal recycling systems, which may leave them more exposed when that route gets blocked. Mouse experiments in breast and prostate cancer models backed this up, with the combined treatment affecting tumor behavior more than either drug alone.

Behind the 31% figure mentioned earlier is a database of health records at Clalit Health Services in Israel, covering roughly five million people over two decades. To be sure the effect wasn’t just a coincidence of who happens to take Viagra, that patient group was matched against similar non-users on income level, weight, health conditions, and cancer type before the survival numbers were calculated. As a further check, researchers looked at whether an unrelated drug called papaverine produced any similar benefit. It didn’t, supporting the idea that the effect is specific to this drug class rather than some other factor about the patients who take it.

Cancer stage at diagnosis wasn’t tracked in the database, a real gap, and people who got sildenafil outside the formal healthcare system went uncounted. Retrospective studies, however carefully designed, can’t fully prove cause and effect the way a clinical trial can.

Together, the lab work, animal studies, and health-record findings give researchers reason to test the combination in clinical trials. A medication with decades of safety data behind it warrants a closer look as a possible companion to existing cancer treatments. A familiar drug’s second act as a cancer-fighting agent is a reminder that useful treatments sometimes turn up where no one thought to look.

---

Disclaimer: This article is based on findings from a peer-reviewed study and is intended for informational purposes only. It does not constitute medical advice. Sildenafil is not an approved cancer treatment, and individuals should consult a physician before making any changes to their medication or treatment plans.

---

---